Clinical Support Services for the NIAMS Intramural Research Program

NIAMS 校内研究项目的临床支持服务

基本信息

批准号：
8344993
负责人：
Richard M Siegel
金额：
$ 411.21万
依托单位：
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/8344993
关键词：
Adult Adult Dermatomyositis Ambulatory Care Facilities Ankylosing spondylitis Appointments and Schedules Arthritis Atherosclerosis Clinical Clinical Protocols Clinical Research Communities Community Health Centers Contracts Cross-Sectional Studies Databases Dermatomyositis Disease District of Columbia Familial Mediterranean Fever Functional disorder Genetic Genetic Determinism Hospitalists Inflammatory Institutional Review Boards Insulin Resistance Interleukin-1 Intramural Research Program Kineret Longitudinal Studies Medical Minority National Institute of Arthritis and Musculoskeletal and Skin Diseases Natural History Neonatal Nurse Practitioners Nursing Research Pathogenesis Patients Physicians Pilot Projects Polymyositis Preparation Randomized Refractory Research Research Activity Research Infrastructure Research Support Rheumatism Rheumatoid Arthritis Rheumatology Salivary Glands Sampling Services Severities Sjogren&apos s Syndrome Spinal Fusion Syndrome Systemic Lupus Erythematosus Therapeutic Training Programs Translational Research Travel United States National Institutes of Health Woman anakinra cost double-blind placebo controlled trial infliximab open label programs receptor rituximab

项目摘要

This project has provided research infrastructure support for the following clinical protocols: 91-AR-0196 Studies on the Natural History and Pathogenesis of Polymyositis, Dermatomyositis, and Related Diseases 94-AR-0066 Studies of the Pathogenesis and Natural History of Systemic Lupus Erythematosus (SLE) 94-AR-0105 Genetics and Pathophysiology of Familial Mediterranean Fever and Related Disorders 99-D-0070 Natural History of Salivary Gland Dysfunction and Sjogren's Syndrome 00-AR-0222 Studies of the Pathogenesis and Natural History of Arthritis and Related Conditions 01-AR-0227 Natural History of Rheumatic Disease in Minority Communities 02-AR-0156 A Randomized, Double-Blind, Placebo-Controlled Trial of Infliximab in Patients with Dermatomyositis and Polymyositis 03-AR-0130 Genetic Determinants of Ankylosing Spondylitis Severity - Cross Sectional Study 03-AR-0131 Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study 03-AR-0133 Clinically Important Changes in Rheumatoid Arthritis 03-AR-0173 Studies of the Natural History and Pathogenesis of Neonatal Onset Multisystem Inflammatory Disease (NOMID) 03-AR-0298 A Pilot Study of the IL-1 Receptor Antagonist Anakinra/Kineret in Patients with Neonatal Onset Multisystem Inflammatory Disease (NOMID/CINCA Syndrome) 04-AR-0205 Progression of Spinal Fusion in Ankylosing Spondylitis 05-AR-0014 A Pilot Open-Label Study of IL-1 Trap in Adult Subjects with Autoinflammatory Disease: A Therapeutic Approach to Study Pathogenesis 07-E-0012 Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Polymyositis (PM) 08-AR-0008 Insulin Resistance and Atherosclerosis in a Sample of Women with Systemic Lupus Erythematosus 08-AR-0218 Rilonacept to Treat Familial Mediterranean Fever 09-AR-0066 Canakinumab to Treat Neonatal Onset Multisystem Inflammatory Disease

该项目为以下临床方案提供了研究基础设施支持： 91-AR-0196关于多肌炎，皮肤炎和相关疾病的自然病史和发病机理的研究 94-AR-0066关于全身性红斑狼疮（SLE）的发病机理和自然历史的研究 94-AR-0105家族性地中海热和相关疾病的遗传学和病理生理学 99-D-0070唾液腺功能障碍的自然史和Sjogren综合征 00-AR-0222关于关节炎和相关疾病的发病机理和自然史的研究 01-AR-0227少数民族疾病的自然历史 02-ar-0156艾弗利昔单抗的一项随机，双盲，安慰剂对照试验对皮肌炎和多聚肌炎患者 03-AR-0130强直性脊柱炎严重程度的遗传决定因素 - 横截面研究 03-AR-0131强直性脊柱炎严重程度的遗传决定因素 - 纵向研究 03-AR-0133类风湿关节炎的临床上重要变化 03-AR-0173关于新生儿发作多系统炎症性疾病（NOMID）的自然病史和发病机理的研究 03-AR-0298 IL-1受体拮抗剂Anakinra/Kineret的试点研究对新生儿发作多系统炎症性疾病（NOMID/CINCA综合征）的患者 04-AR-0205强直性脊柱炎中脊柱融合的进展 05-ar-0014一项自发疾病成人受试者IL-1陷阱的试验性开放标签研究：一种研究发病机理的治疗方法 07-e-0012利妥昔单抗治疗难治性成人和少年性皮肌炎（DM）和多肌炎（PM）全身性红斑狼疮的女性样本中的08-ar-0008胰岛素抵抗和动脉粥样硬化 08-ar-0218 Rilonacept治疗家族性地中海发烧 09-ar-0066 canakinumab治疗新生儿发作多系统炎症疾病